AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36448475 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills monitoring with just-in-time adaptive interventions
Number of subjects: 264
Study 34284312 — intervention group
Group type: EXPERIMENTAL
Intervention: JUUL e‐cigarettes
Number of subjects: 187
Study 34284312 — intervention group
Group type: COMPARATOR
Intervention: Cigarettes as usual
Number of subjects: 187
Study 35907175 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate/ursodoxicoltaurine
Number of subjects: 0
Study 35907175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33137150 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (2005 International Diabetes Federation criteria)
Number of subjects: 343
Study 33137150 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (revised ATP III criteria)
Number of subjects: 343
Study 33137150 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (2009 harmonized criteria)
Number of subjects: 343
Study 33137150 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 343
Study 33137150 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of red meat
Number of subjects: 343
Study 33137150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary leisure time activity
Number of subjects: 343
Study 33137150 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee intake
Number of subjects: 343
Study 33137150 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥ 25 kg/m2
Number of subjects: 343
Study 33137150 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 40-49 years
Number of subjects: 343
Study 33137150 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 50-59 years
Number of subjects: 343
Study 33137150 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥ 70 years
Number of subjects: 343
Study 34768161 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐α + Sargramostim (IFN)
Number of subjects: 34
Study 34768161 — intervention group
Group type: COMPARATOR
Intervention: K562/GM‐CSF vaccine
Number of subjects: 34
Study 34768161 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant IFN (including crossover)
Number of subjects: 34
Study 32087684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Sucrosomial® iron
Number of subjects: 99
Study 32087684 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) iron gluconate
Number of subjects: 99
Study 32087684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost comparison
Number of subjects: 99
Study 32087684 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analysis
Number of subjects: 99
Study 33973256 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces with distinctive features (e.g., tattoos)
Number of subjects: 0
Study 33973256 — intervention group
Group type: COMPARATOR
Intervention: Faces without distinctive features
Number of subjects: 0
Study 33245807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues to experience nature (e.g., smell flowers, observe wildlife, turn off your phone)
Number of subjects: 1023
Study 33245807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cues to experience nature (e.g., smell and touch natural elements)
Number of subjects: 1023
Study 35139101 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention
Number of subjects: 234
Study 35139101 — intervention group
Group type: EXPERIMENTAL
Intervention: Written summary of evidence
Number of subjects: 234
Study 35139101 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information)
Number of subjects: 234
Study 34557142 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (INDAK, nutrition counseling, vascular risk management)
Number of subjects: 605
Study 34557142 — intervention group
Group type: COMPARATOR
Intervention: Usual vascular care advice and referral (Control)
Number of subjects: 605
Study 33371022 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation (4-6 weeks) including exercise training, nutrition counselling, respiratory physiotherapy, and mindfulness sessions
Number of subjects: 160
Study 33371022 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 160
Study 35135308 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted apixaban
Number of subjects: 674
Study 35135308 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist therapy
Number of subjects: 674
Study 35135308 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted apixaban and Vitamin K antagonist therapy
Number of subjects: 674
Study 33508849 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Number of subjects: 535
Study 33508849 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel
Number of subjects: 535
Study 33508849 — intervention group
Group type: COMPARATOR
Intervention: Lanreotide
Number of subjects: 535
Study 35278201 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwell group culture
Number of subjects: 532
Study 32196696 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIRATE guidelines checklist and flowchart
Number of subjects: 51
Study 32196696 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIRATE guidelines
Number of subjects: 51
Study 34533841 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (4 mg)
Number of subjects: 0
Study 34533841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35713447 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional antiemetic therapy alone
Number of subjects: 0
Study 35713447 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional antiemetic therapy in combination with ginger (2 different concentrations)
Number of subjects: 0
Study 35790016 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy (control arm of five RCTs: ASCENT 2, VENICE, CELGENE/MAINSAIL, ENTHUSE 14, ENTHUSE 33)
Number of subjects: 2336
Study 33792400 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 28
Study 33792400 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28
Study 33792400 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising Control
Number of subjects: 28
Study 33792400 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT and HIIT
Number of subjects: 28
Study 32374442 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-based learning (CBL)
Number of subjects: 2
Study 32374442 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based learning (LBL)
Number of subjects: 2
Study 36054319 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Calcipotriol/Betamethasone foam
Number of subjects: 30
Study 36054319 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone foam alone
Number of subjects: 30
Study 36054319 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol Propionate ointment
Number of subjects: 30
Study 36054319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32202920 — intervention group
Group type: EXPERIMENTAL
Intervention: Our Family Our Future intervention
Number of subjects: 73
Study 32202920 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 73
Study 37753555 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief-motivational interviewing (MI)
Number of subjects: 58
Study 37753555 — intervention group
Group type: COMPARATOR
Intervention: Traditional oral hygiene instructions (OHI)
Number of subjects: 58
Study 34758629 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-Formulated Ketogenic Diet (WFKD)
Number of subjects: 24
Study 34758629 — intervention group
Group type: COMPARATOR
Intervention: Whole-Food Diet (WFD)
Number of subjects: 24
Study 34651102 — intervention group
Group type: EXPERIMENTAL
Intervention: E-SBIRT intervention and pamphlet
Number of subjects: 240
Study 34651102 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet of drug abuse prevention
Number of subjects: 240
Study 35703895 — intervention group
Group type: EXPERIMENTAL
Intervention: BreatheWell Wear and conventional care
Number of subjects: 30
Study 35703895 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 30
Study 34181182 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial intelligence model
Number of subjects: 301
Study 34181182 — intervention group
Group type: COMPARATOR
Intervention: Maximum standardized uptake value
Number of subjects: 301
Study 32363613 — intervention group
Group type: EXPERIMENTAL
Intervention: RHT3201 (1.0 × 10^10 CPU/d)
Number of subjects: 66
Study 32363613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 32363613 — intervention group
Group type: EXPERIMENTAL
Intervention: RHT3201
Number of subjects: 66
Study 32363613 — intervention group
Group type: COMPARATOR
Intervention: RHT3201 and Placebo
Number of subjects: 66
Study 36028775 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual nutrition therapy (five in-person visits and three phone calls) and freely delivered energy- and protein-rich foods
Number of subjects: 106
Study 33636344 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention including nudges within the electronic health record (EHR) such as accountable justification, precommitment to address high-risk prescriptions, and PainTracker.
Number of subjects: 0
Study 33636344 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no EHR-based intervention.
Number of subjects: 0
Study 32561245 — intervention group
Group type: EXPERIMENTAL
Intervention: AD/IMH/PAU patients
Number of subjects: 133
Study 32561245 — intervention group
Group type: COMPARATOR
Intervention: Population referents
Number of subjects: 133
Study 36104145 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported Prep-to-Play intervention (with physiotherapist support)
Number of subjects: 140
Study 36104145 — intervention group
Group type: COMPARATOR
Intervention: Unsupported phase (usual routines, no face-to-face support)
Number of subjects: 140
Study 33407797 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared follow-up care intervention (GOSPEL I)
Number of subjects: 60
Study 33407797 — intervention group
Group type: COMPARATOR
Intervention: Usual specialist‐led follow-up care
Number of subjects: 60
Study 33184653 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational phosphatidylcholine supplementation
Number of subjects: 25
Study 33184653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 32154888 — intervention group
Group type: EXPERIMENTAL
Intervention: Written resources
Number of subjects: 611
Study 32154888 — intervention group
Group type: EXPERIMENTAL
Intervention: Written resources plus in-person assistance
Number of subjects: 611
Study 35468299 — intervention group
Group type: EXPERIMENTAL
Intervention: Thulium laser (multiple shots) in group A
Number of subjects: 148
Study 35468299 — intervention group
Group type: COMPARATOR
Intervention: Thulium laser (one shot with a manual perforator) in group B
Number of subjects: 148
Study 33212438 — intervention group
Group type: EXPERIMENTAL
Intervention: IG2: motivation‐based intervention with end‐of‐life perspective
Number of subjects: 168
Study 33212438 — intervention group
Group type: EXPERIMENTAL
Intervention: IG3: combination of IG1 and IG2
Number of subjects: 168
Study 33212438 — intervention group
Group type: COMPARATOR
Intervention: CG: control group
Number of subjects: 168
Study 33212438 — intervention group
Group type: EXPERIMENTAL
Intervention: IG1: value‐based intervention with end‐of‐life perspective
Number of subjects: 168
Study 33175238 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling based on the PLISSIT model (4 sessions, 45-75 min each)
Number of subjects: 62
Study 33175238 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 62
Study 32798761 — intervention group
Group type: EXPERIMENTAL
Intervention: Layer‐by‐layer wound irrigation with gentamicin‐saline solution
Number of subjects: 205
Study 32798761 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound irrigation with saline solution
Number of subjects: 205
Study 32798761 — intervention group
Group type: COMPARATOR
Intervention: No irrigation (Control group)
Number of subjects: 205
Study 32034857 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic per-postconditioning (RIperpostC)
Number of subjects: 115
Study 32034857 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 115
Study 32599066 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mediastinal staging
Number of subjects: 332
Study 33729499 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 280
Study 33729499 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step Mendelian randomization (MR) analyses
Number of subjects: 280
Study 33729499 — intervention group
Group type: COMPARATOR
Intervention: DNA methylation
Number of subjects: 280
Study 36179657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cascading deep supervision U-Net (CSNet) model
Number of subjects: 162
Study 36179657 — intervention group
Group type: COMPARATOR
Intervention: Traditional U-Net model
Number of subjects: 162
Study 36179657 — intervention group
Group type: COMPARATOR
Intervention: Supervision U-Net (SNet) model
Number of subjects: 162
Study 33892287 — intervention group
Group type: EXPERIMENTAL
Intervention: Aberrant Behavior Checklist (ABC)
Number of subjects: 122
Study 34524103 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPACT intervention (app-based program)
Number of subjects: 80
Study 34524103 — intervention group
Group type: COMPARATOR
Intervention: Enhanced web-based resources (control)
Number of subjects: 80
Study 32359506 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous HSCT
Number of subjects: 1503
Study 32359506 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib-melphalan-prednisone (VMP)
Number of subjects: 1503
Study 32359506 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-lenalidomide-dexamethasone (VRD) consolidation therapy
Number of subjects: 1503
Study 32359506 — intervention group
Group type: COMPARATOR
Intervention: No consolidation
Number of subjects: 1503
Study 32359506 — intervention group
Group type: COMPARATOR
Intervention: VMP
Number of subjects: 1503
Study 35463507 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal and non-verbal de-escalation training for staff teams on experimental wards
Number of subjects: 0
Study 35463507 — intervention group
Group type: COMPARATOR
Intervention: Control group (no de-escalation training)
Number of subjects: 0
Study 32495862 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of miR‐18a in OC cells
Number of subjects: 0
Study 32495862 — intervention group
Group type: EXPERIMENTAL
Intervention: Restoration of miR‐18a
Number of subjects: 0
Study 32495862 — intervention group
Group type: COMPARATOR
Intervention: Low miR‐18a expression
Number of subjects: 0
Study 34527078 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg daily)
Number of subjects: 16
Study 34527078 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (600 mg daily)
Number of subjects: 16
Study 34527078 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline measurements)
Number of subjects: 16
Study 32513507 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist- and nurse-driven metabolic monitoring protocol
Number of subjects: 160
Study 36257695 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice support curriculum delivered by trained practice coaches, including a kickoff meeting, 3 months of intensive support, 9 months of ongoing support, and access to online learning materials and expert faculty.
Number of subjects: 264
Study 36257695 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice support curriculum delivered by trained practice coaches.
Number of subjects: 264
Study 33263418 — intervention group
Group type: EXPERIMENTAL
Intervention: Margetuximab plus retifanlimab with/without chemotherapy
Number of subjects: 0
Study 33263418 — intervention group
Group type: EXPERIMENTAL
Intervention: Margetuximab plus tebotelimab with chemotherapy
Number of subjects: 0
Study 32521394 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion
Number of subjects: 80
Study 32521394 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 35972164 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow music (study arm B)
Number of subjects: 600
Study 35972164 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast music (study arm C)
Number of subjects: 600
Study 35972164 — intervention group
Group type: COMPARATOR
Intervention: No music (study arm A)
Number of subjects: 600
Study 35972164 — intervention group
Group type: EXPERIMENTAL
Intervention: All study arms
Number of subjects: 600
Study 34341242 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 40
Study 34341242 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemomechanical removal (Papaya® gel)
Number of subjects: 40
Study 32372118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (15 mg/kg)
Number of subjects: 195
Study 32372118 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular TXA (2 g)
Number of subjects: 195
Study 32372118 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 195
Study 32372118 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients > 65 years
Number of subjects: 195
Study 32488361 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-leg modified lateral position (SL-MLP)
Number of subjects: 124
Study 32488361 — intervention group
Group type: COMPARATOR
Intervention: Standard prone position (PP)
Number of subjects: 124
Study 32488361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study 34030169 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg daily, up-titrated after 25 mg daily for 1 week)
Number of subjects: 74
Study 34030169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 35781129 — intervention group
Group type: EXPERIMENTAL
Intervention: Single, high‐dose intravenous iron therapy (20 mg/kg ferric derisomaltose)
Number of subjects: 110
Study 35781129 — intervention group
Group type: COMPARATOR
Intervention: Oral iron supplementation (100 mg ferrous sulphate orally twice daily)
Number of subjects: 110
Study 34354033 — intervention group
Group type: EXPERIMENTAL
Intervention: Accountable Care Team (ACT) intervention
Number of subjects: 0
Study 34354033 — intervention group
Group type: COMPARATOR
Intervention: Control group (units not implementing ACT)
Number of subjects: 0
Study 34354033 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT intervention
Number of subjects: 0
Study 36355805 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizanlizumab 5.0 mg/kg
Number of subjects: 57
Study 36355805 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizanlizumab 7.5 mg/kg
Number of subjects: 57
Study 34684650 — intervention group
Group type: EXPERIMENTAL
Intervention: Water supplementation group (1000 mL purified water)
Number of subjects: 76
Study 34684650 — intervention group
Group type: EXPERIMENTAL
Intervention: Water supplementation group (500 mL purified water)
Number of subjects: 76
Study 34684650 — intervention group
Group type: EXPERIMENTAL
Intervention: Water supplementation group (200 mL purified water)
Number of subjects: 76
Study 34684650 — intervention group
Group type: COMPARATOR
Intervention: No water supplementation group (NW group)
Number of subjects: 76
Study 34684650 — intervention group
Group type: COMPARATOR
Intervention: Dehydration test
Number of subjects: 76
Study 32749468 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Memory Reactivation (EMR‐ECT)
Number of subjects: 66
Study 32749468 — intervention group
Group type: COMPARATOR
Intervention: Control Memory Reactivation (CMR‐ECT)
Number of subjects: 66
Study 33583493 — intervention group
Group type: EXPERIMENTAL
Intervention: AASM criteria
Number of subjects: 50
Study 33583493 — intervention group
Group type: EXPERIMENTAL
Intervention: Randerath algorithm
Number of subjects: 50
Study 35685548 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model based on enhanced T1WI
Number of subjects: 114
Study 34618889 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative paravertebral block with 0.35 ml/kg 0.75% ropivacaine
Number of subjects: 380
Study 34618889 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 380
Study 32086874 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethmoidal drug-eluting stent (DES) with triamcinolone acetonide stents (n = 34)
Number of subjects: 63
Study 32086874 — intervention group
Group type: COMPARATOR
Intervention: Topical intranasal corticosteroid (triamcinolone acetonide nasal spray) (n = 29)
Number of subjects: 63
Study 34669935 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) intervention
Number of subjects: 436
Study 34669935 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating (HE) intervention
Number of subjects: 436
Study 34669935 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 436
Study 32133871 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored physical activity intervention
Number of subjects: 822
Study 32133871 — intervention group
Group type: COMPARATOR
Intervention: Control group (norm-active participants)
Number of subjects: 822
Study 34735183 — intervention group
Group type: EXPERIMENTAL
Intervention: eBook with a character who modeled dialogic questioning (experimental)
Number of subjects: 73
Study 34735183 — intervention group
Group type: COMPARATOR
Intervention: eBook without modeling (control)
Number of subjects: 73
Study 34735183 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice condition (choose between versions)
Number of subjects: 73
Study 34226654 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH, Genotonorm 0.4 mg, Pfizer Pharmaceuticals) administered subcutaneously daily for one year
Number of subjects: 0
Study 34226654 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered subcutaneously daily for one year
Number of subjects: 0
Study 34226654 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive and long-lasting rehabilitation program
Number of subjects: 0
Study 32925060 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 20
Study 32925060 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20